Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment After Autologous Hematopoietic Stem Cell Transplantation in Children With Neuroblastoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is: · Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \> 100\*10\^9/L.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 18
Healthy Volunteers: f
View:
• Age\<18 years old;
• Diagnosed as neuroblastoma;
• ECOG ≤ 2;
• First time receiving autologous hematopoietic stem cell transplantation;
• The subjects or their legal guardians agree to participate and sign the informed consent form.
Locations
Other Locations
China
Department of Stem Cell Transplantation, Beijing Children's Hospital, Capital Medical University
RECRUITING
Beijing
Contact Information
Primary
Dr. Yang
yangjundabby@outlook.com
86-010-59617614
Time Frame
Start Date: 2024-06-30
Estimated Completion Date: 2027-07-31
Participants
Target number of participants: 30
Treatments
Experimental: Experimental group
Related Therapeutic Areas
Sponsors
Leads: Beijing Children's Hospital